Our study found that ANK3 low expression was highly correlated with better cancer disease-specific survival (DSS), overall patient survival (OS) and progression-free survival (PFS) in adrenocortical carcinoma (ACC), colon cancer (COAD), kidney clear cell carcinoma (KIRC) and head and neck squamous cell carcinoma (HNSC). Here, ANK3 is linked to clear cell renal carcinoma.